PMID- 38041893
OWN - NLM
STAT- MEDLINE
DCOM- 20240315
LR  - 20240315
IS  - 1532-818X (Electronic)
IS  - 0196-0709 (Linking)
VI  - 45
IP  - 2
DP  - 2024 Mar-Apr
TI  - Short-term and long-term efficacy of sublingual immunotherapy in different 
      courses for house dust mite-induced allergic rhinitis.
PG  - 104118
LID - S0196-0709(23)00332-0 [pii]
LID - 10.1016/j.amjoto.2023.104118 [doi]
AB  - PURPOSE: Sublingual immunotherapy (SLIT) has been proven to be an effective and 
      safe treatment for patients with house dust mite (HDM)-induced allergic rhinitis 
      (AR) to achieve short-term and long-term efficacy. This study aimed to 
      investigate the relationship between SLIT duration and long-term efficacy. 
      MATERIALS AND METHODS: This study involved 134 patients who underwent SLIT 
      between 2019 and 2021 (in the 2-year group), between 2018 and 2021(in the 3-year 
      group), or between 2017 and 2021 (in the 4-year group). The total nasal symptoms 
      score (TNSS), total medication score (TMS), visual analogue scale (VAS), the Mini 
      Rhinoconjunctivitis Quality of Life Questionnaire (MiniRQLQ) and adverse events 
      (AEs) were assessed at baseline, after treatment (2021) and one year after the 
      treatment completion (2022). The correlation between MiniRQLQ and other 
      indicators was also analyzed. RESULTS: After SLIT, patients in all three groups 
      showed significant improvements in TNSS, TMS, VAS and MiniRQLQ scores (all 
      p < 0.001). These improvements were sustained even one year after SLIT. Patients 
      who received 3-4 years of SLIT showed significant improvement compared with those 
      who received 2 years of SLIT in all clinical outcomes (all p < 0.01). The 
      analysis showed positive correlations between the MiniRQLQ and TNSS, TMS, and VAS 
      (all p < 0.001). No significant difference was observed in the AE rate in all 
      three groups (p > 0.05). CONCLUSION: Different duration of HDM SLIT could 
      generate various short-term and long-term clinical efficacy. The MiniRQLQ could 
      be applied to evaluate SLIT efficacy in clinical practice.
CI  - Copyright (c) 2023. Published by Elsevier Inc.
FAU - Yang, Jie
AU  - Yang J
AD  - Department of Otorhinolaryngology Head and Neck Surgery, Hainan General Hospital, 
      Hainan Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China.
FAU - Zheng, Jing
AU  - Zheng J
AD  - Department of Otorhinolaryngology Head and Neck Surgery, Hainan General Hospital, 
      Hainan Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China.
FAU - Zhou, Yu
AU  - Zhou Y
AD  - Department of Otorhinolaryngology Head and Neck Surgery, Hainan General Hospital, 
      Hainan Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China.
FAU - Qiu, Quan
AU  - Qiu Q
AD  - Department of Otorhinolaryngology Head and Neck Surgery, Hainan General Hospital, 
      Hainan Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China.
FAU - Zhan, Jiabin
AU  - Zhan J
AD  - Department of Otorhinolaryngology Head and Neck Surgery, Hainan General Hospital, 
      Hainan Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China.
FAU - Wei, Xin
AU  - Wei X
AD  - Department of Otorhinolaryngology Head and Neck Surgery, Hainan General Hospital, 
      Hainan Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China. 
      Electronic address: hnweking@sina.com.
LA  - eng
PT  - Journal Article
DEP - 20231124
PL  - United States
TA  - Am J Otolaryngol
JT  - American journal of otolaryngology
JID - 8000029
RN  - 0 (Antigens, Dermatophagoides)
SB  - IM
MH  - Humans
MH  - Animals
MH  - *Sublingual Immunotherapy
MH  - Quality of Life
MH  - Antigens, Dermatophagoides/therapeutic use
MH  - *Hypersensitivity/drug therapy
MH  - *Rhinitis, Allergic, Perennial/therapy
MH  - Treatment Outcome
MH  - Pyroglyphidae
MH  - *Rhinitis, Allergic/drug therapy
OTO - NOTNLM
OT  - Allergen-specific immunotherapy
OT  - Allergic rhinitis
OT  - House dust mite
OT  - Long-term efficacy
OT  - Short-term efficacy
OT  - Sublingual immunotherapy
COIS- Declaration of competing interest All authors declare no financial or commercial 
      conflicts of interest.
EDAT- 2023/12/03 00:42
MHDA- 2024/03/15 06:43
CRDT- 2023/12/02 18:01
PHST- 2023/08/08 00:00 [received]
PHST- 2023/11/13 00:00 [revised]
PHST- 2023/11/19 00:00 [accepted]
PHST- 2024/03/15 06:43 [medline]
PHST- 2023/12/03 00:42 [pubmed]
PHST- 2023/12/02 18:01 [entrez]
AID - S0196-0709(23)00332-0 [pii]
AID - 10.1016/j.amjoto.2023.104118 [doi]
PST - ppublish
SO  - Am J Otolaryngol. 2024 Mar-Apr;45(2):104118. doi: 10.1016/j.amjoto.2023.104118. 
      Epub 2023 Nov 24.